(The Hill) — The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk’s Wegovy and Lilly’s Zepbound, for a […]
Related Posts
-
Public defender sues state claiming she was fired for Kirk-related comments
The State of Iowa is being sued by an attorney who claims she was fired…
-
Top US military officials are visiting Caribbean leaders as Trump weighs next steps
Top U.S. military officials meet Caribbean leaders as the U.S. has carried out 21 strikes…
-
Eurobites: Nokia, Telefónica seal five-year RAN deal in Germany
Also in today’s EMEA regional roundup: Orange Business pushes sovereign cloud; DT sidles closer to…
-
DOCSIS 3.1 leaves its predecessor in the dust
OpenVault’s latest ‘Broadband Insights Report’ takes a deep dive into the world of cable tech,…
Leave a Reply